Sanofi Provides Update on Lixisenatide NDA in U.S.

Sanofi announce decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S., which included early interim results from the ongoing ELIXA cardiovascular (CV) outcomes study. The company plans to resubmit the NDA in 2015, after completion of the ELIXA CV study (Sanofi Aventis)